GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis

European Journal of Neurology

Volumn 23, Issue 8, 2016, Pages 1372-1379

  Xie, Y ^a,b   Meng, Y ^c   Li, H F ^d   Hong, Y ^e   Sun, L ^f   Zhu, X ^f   Yue, Y X ^d   Gao, X ^e   Wang, S ^a   Li, Y ^a   Kusner, L L ^g   Kaminski, H J ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d SHANDONG UNIVERSITY   (China)

^e QINGDAO UNIVERSITY   (China)

^f BEIJING HOSPITAL   (China)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

glucocorticoid receptor; myasthenia gravis; single nucleotide polymorphism; treatment efficacy; variability

Indexed keywords

GLUCOCORTICOID;

ADULT; AGED; ALLELISM; ARTICLE; CHINESE; COHORT ANALYSIS; DISEASE DURATION; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 84978522059     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13040     Document Type: Article

References (34)

1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475–490.
2. Kumar V, Kaminski HJ. Treatment of myasthenia gravis. Curr Neurol Neurosci Rep 2011; 11: 89–96.
3. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15: 291–298.
4. Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992; 32: 37–43.
5. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893–902.
6. Quax RA, Manenschijn L, Koper JW, et al. Glucocorticoid sensitivity in health and disease. Nat Rev Endocrinol 2013; 9: 670–686.
7. Encío IJ, Detera-Wadleigh SD. The genomic structure of the human glucocorticoid receptor. J Biol Chem 1991; 266: 7182–7188.
8. Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci 2009; 1179: 179–198.
9. Koper JW, van Rossum EF, van den Akker EL. Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease. Steroids 2014; 92: 62–73.
10. Chen HL, Li LR. Glucocorticoid receptor gene polymorphisms and glucocorticoid resistance in inflammatory bowel disease: a meta-analysis. Dig Dis Sci 2012; 57: 3065–3075.
11. Zou YF, Xu JH, Wang F, et al. Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study. Autoimmunity 2013; 46: 531–536.
12. Aarli JA. Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci 2008; 1132: 238–243.
13. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55: 16–23.
14. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998; 841: 769–772.
15. Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005; 64: 1968–1970.
16. Han B, Kang HM, Seo MS, Zaitlen N, Eskin E. Efficient association study design via power-optimized tag SNP selection. Ann Hum Genet 2008; 72: 834–847.
17. Charmandari E, Kino T, Ichijo T, Zachman K, Alatsatianos A, Chrousos GP. Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGRalphaR477H and hGRalphaG679S associated with generalized glucocorticoid resistance. J Clin Endocrinol Metab 2006; 91: 1535–1543.
18. Krupoves A, Mack D, Deslandres C, Seidman E, Amre DK. Variation in the glucocorticoid receptor gene (NR3C1) may be associated with corticosteroid dependency and resistance in children with Crohn's disease. Pharmacogenet Genomics 2011; 21: 454–460.
19. Huang LC, Hsu SY, Lin E. A comparison of classification methods for predicting chronic fatigue syndrome based on genetic data. J Transl Med 2009; 7: 81.
20. Oakley RH, Cidlowski JA. Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 2011; 286: 3177–3184.
21. Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635–641.
22. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010; 75: 1–12.
23. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95: 2435–2441.
24. Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci 2006; 1069: 1–9.
25. Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 2009; 300: 7–16.
26. Quax RA, Koper JW, Huisman AM, et al. Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis. Rheumatol Int 2015; 35: 1325–1333.
27. Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 2013; 34: 518–530.
28. Syed AA, Irving JA, Redfern CP, et al. Low prevalence of the N363S polymorphism of the glucocorticoid receptor in South Asians living in the United Kingdom. J Clin Endocrinol Metab 2004; 89: 232–235.
29. Wang LL, Xie YC, Hou SF, et al. Association of glucocorticoid receptor gene polymorphism with myasthenia gravis. Zhonghua Kou Qiang Yi Xue Za Zhi 2009; 89: 3035–3037.
30. Chen JM, Férec C, Cooper DN. A systematic analysis of disease-associated variants in the 3′ regulatory regions of human protein-coding genes I: general principles and overview. Hum Genet 2006; 120: 1–21.
31. Derijk RH, de Kloet ER. Corticosteroid receptor polymorphisms: determinants of vulnerability and resilience. Eur J Pharmacol 2008; 583: 303–311.
32. Pietras T, Panek M, Tworek D, et al. The Bcl I single nucleotide polymorphism of the human glucocorticoid receptor gene h-GR/NR3C1 promoter in patients with bronchial asthma: pilot study. Mol Biol Rep 2011; 38: 3953–3958.
33. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003; 60: 243–248.
34. Gronseth GS, Barohn RJ. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7–15.